Molecular target therapy for synovial sarcoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The specific chromosomal translocation and SYT-SSX fusion gene in synovial sarcoma (SS) are known, but the molecular mechanisms driving its development are not fully understood.
• Synovial sarcoma is a soft-tissue tumor.
• Neural crest cells are a potential cell of origin for SS.

Purpose of the Study:

• To investigate the molecular mechanisms underlying synovial sarcoma tumorigenesis.
• To identify genes specifically upregulated in SS that contribute to tumor cell proliferation.
• To explore potential therapeutic targets for synovial sarcoma.

Main Methods:

• Gene-expression profiling using cDNA microarray analysis of soft-tissue tumors.
• Comparative analysis of gene-expression patterns between SS and other sarcomas, including malignant peripheral nerve sheath tumors.
• Identification and validation of upregulated genes in SS.

Main Results:

• Synovial sarcoma exhibits a distinct gene-expression pattern compared to other sarcomas.
• The gene-expression pattern of SS is similar to that of malignant peripheral nerve sheath tumors, suggesting a neural crest origin.
• Several genes were found to be specifically upregulated in SS, implicating them in SS cell proliferation.
• Frizzled homolog 10 was identified as a significantly upregulated gene in SS.

Conclusions:

• Synovial sarcoma likely originates from neural crest cells.
• Frizzled homolog 10 is a key molecule involved in SS cell proliferation.
• Frizzled homolog 10 represents a promising molecular target for developing novel therapies for synovial sarcoma.